Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors.
Maddalena CentanniSreenath M KrishnanLena E FribergPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Dose adjustments based on the pharmacodynamic biomarkers neutrophil count and sVEGFR-3 can increase OS while retaining drug safety. Future efforts could explore the possibility of incorporating a model-based dose approach in clinical practice to increase dosing accuracy for these biomarkers.